Dyadic International Inc., DE
DYAI
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.64M
Close$
$-0.36
174.5% downside
Current Fair Value
174.5% downsideOvervalued by 174.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.64 Million |
|---|---|
| Enterprise Value | $22.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.23 |
| Beta | 1.15 |
| Outstanding Shares | 36,438,703 |
Return
| Return on Equity | 319.27% |
|---|---|
| Return on Assets | -116.60% |
| Return on Invested Capital | -281.82% |
Valuation & Multiples
| P/E Ratio | -2.27 |
|---|---|
| PEG | -12.33 |
| Price to Sales | - |
| Price to Book Ratio | -0.48 |
| Enterprise Value to Revenue | 5.05 |
| Enterprise Value to EBIT | -3.05 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | -2.77 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$1.03 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$1.43 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 68,800▼ 5.62% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.69%▼ 1.43% |
|---|---|
| Total Invested | $4.14M▼ 1.67% |
| Investors Holding | 40▲ 3.00% |
ESG Score
No data
About Dyadic International Inc., DE
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly ...